Why do some researchers report no noticeable effects from the MOTS-c 5-amino-1MQ stack
The BPC-157 Regulatory Timeline Why the April change was often misunderstood When FDA removed BPC-157 from Category 2 in April, some online posts described the change as permission to compound again
Thromb Haemost 96:488491 Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, Abramov A, Maclouf J, Godefray YC, de Raucourt E, Guillin MC (1999) A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood
BPC-157 is supplied as a lyophilized (freeze-dried) powder in a sterile glass vial sealed with a rubber stopper
During recovery from surgery or strain